Courtney M.W. Tygesson

Courtney is a founding partner of Cooley’s Chicago office, where she advises her clients in equity, debt and other capital markets transactions, as well as corporate governance and securities law matters. She is a trusted adviser to public and private companies across a range of industries, with an emphasis on the technology and life sciences sectors. She also represents top investment banks.

Courtney’s extensive capital markets experience includes representing issuers and underwriters in initial public offerings, secondary equity offerings, high-yield, investment-grade and convertible debt offerings, tender offers, and other capital markets transactions. She also advises public companies on securities and corporate law matters, including Securities and Exchange Commission compliance, Exchange Act periodic reports, disclosure issues, Sarbanes-Oxley Act compliance, corporate governance matters, stock exchange requirements, proxy statement planning and preparation, Rule 144 issues, and Section 13 and Section 16 reporting obligations.

Courtney’s representative transactions include advising:

• Harpoon Therapeutics on its $150 million PIPE offering
• The underwriters in Vistagen Therapeutics’ $100 million follow-on offering
• The underwriters in Vivid Seats’ $133 million follow-on offering and $128 million follow-on offering
• RAPT Therapeutics on its $75 million follow-on offering
• The underwriters in Optinose’s $57.5 million follow-on offering
• NETSTREIT on its:
  • $210 million follow-on offering
  • $230 million follow-on offering
  • $225 million IPO*
• The underwriters in DICE Therapeutics’ $345 million follow-on offering and its $235 million IPO
• Adagio Therapeutics on its $356 million IPO
• TPB Acquisition Corp. I on its $180.4 million SPAC IPO
• Sprout Social on its $165 million follow-on offering*
• The underwriters in Sprout Social’s $150 million IPO*

* Representation handled prior to joining Cooley